Newcastle 1000 (NEW1000) Study: an Australian population-based prospective pregnancy cohort study design and protocol
,
Simon Keely,
John Attia,
Andrew Boyle,
Sarah R Valkenborghs,
Roger Smith,
Clare Collins,
Penny Reeves,
John Wiggers,
Joerg Mattes,
Andrew Searles,
Frances Kay-Lambkin,
Linda Campbell,
Vanessa E Murphy,
Peter Gibson,
Craig Gedye,
Tegan Grace,
Rodney Scott,
Kirsty Pringle,
Maralyn Foureur,
Craig E Pennell,
Vanessa McDonald,
Joshua Fisher,
Carol Wang,
Jonathan J Hirst,
Craig Pennell,
Mike Calford,
Vanessa Murphy,
Tracey Dudding-Bythe,
Nick Talley,
Emily Hoedt,
Jay Horvat,
Mitch Duncan,
Sarah Valkenborghs,
Emily Freeman
Affiliations
1Research Evaluation and Audit for Child Health (REACH)
Simon Keely
1 Priority Research Centre for Healthy Lungs and Immune Health Research Program, The University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia
John Attia
2 School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia
Andrew Boyle
Sarah R Valkenborghs
School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, New South Wales, Australia
Roger Smith
Mothers and Babies Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
Clare Collins
Food and Nutrition Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
Penny Reeves
School of Medicine and Public Health, The University of Newcastle, Callaghan, NSW, Australia
John Wiggers
Hunter New England Population Health, Hunter New England Local Health District, Wallsend, New South Wales, Australia
Joerg Mattes
Paediatric Respiratory and Sleep Medicine, John Hunter Children’s Hospital, New Lambton Heights, New South Wales, Australia
Andrew Searles
Frances Kay-Lambkin
Linda Campbell
Vanessa E Murphy
School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia
Peter Gibson
Craig Gedye
Tegan Grace
School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia
Rodney Scott
7Hunter Medical Research Institute, Newcastle University, Callaghan, NSW, Australia
Kirsty Pringle
Maralyn Foureur
Craig E Pennell
School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia
Vanessa McDonald
Joshua Fisher
School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia
Carol Wang
School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia
Jonathan J Hirst
Mothers and Babies Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
Craig Pennell
Mike Calford
Vanessa Murphy
Tracey Dudding-Bythe
Nick Talley
Emily Hoedt
Jay Horvat
1 Priority Research Centre for Healthy Lungs and Immune Health Research Program, The University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia
Introduction Multiple cohort studies have been established to investigate the impact of early life factors on development and health outcomes. In Australia the majority of these studies were established more than 20 years ago and, although longitudinal in nature, are inherently susceptible to socioeconomic, environmental and cultural influences which change over time. Additionally, rapid leaps in technology have increased our understanding of the complex role of gene–environment interactions in life course health, highlighting the need for new cohort studies with repeated biological sampling and in-depth phenotype data across the first 1000 days of life from conception.Methods and analysis The Newcastle 1000 (NEW1000) Study, based in the regional city of Newcastle, New South Wales, was developed after an extensive consultation process involving 3 years of discussion with key stakeholders and healthcare consumer organisations and seven healthcare consumer workshops. This prospective population-based pregnancy cohort study will recruit 500 families per year for 5 years, providing detailed, longitudinal, multisystem phenotyping, repeated ultrasound measures and serial sample collection to investigate healthcare consumer identified health outcomes of priority. Stage 1 will involve recruitment of pregnant participants and their partners at 14 weeks gestation, with dense phenotype data and biological samples collected at 14, 20, 28 and 36 weeks gestation and serial ultrasound measures at 20, 28, 36 and 40 weeks, with postpartum follow-up at 6 weeks and 6 months. Biological samples will be used for biomarker discovery and sequencing of the genome, transcriptome, epigenome, microbiome and metabolome.Ethics and dissemination Ethics approval was obtained from Hunter New England Local Health District Ethics Committee (2020/ETH02881). Outcomes will be published in peer-reviewed journals, disseminated to participants through the NEW1000 website, presented at scientific conferences, and written reports to local, state and national government bodies and key stakeholders in the healthcare system to inform policy and evidence-based practice.
